PHILADELPHIA--(BUSINESS WIRE)--Iroko Holdings, managing member of Iroko Pharmaceuticals and Iroko Cardio, announced today the appointment of Bert van den Bergh as an Executive Board Member. Together with the Iroko team, and a highly experienced advisory team, van den Bergh will focus on the commercialization of Iroko’s biggest selling product, Aggrastat® (tirofiban hydrochloride), a GP IIB/IIIA inhibitor, in territories outside the United States.
